Skip to main content
Terug
CSMYF logo

COSMOS Pharmaceutical Corporation

Datakwaliteit: 100%
Overbought
CSMYF
OTC Healthcare Medical - Pharmaceuticals
€ 48,27
€ 0,00 (0,00%)
Marktkapitalisatie: 3,83B
Dagbereik
€ 48,27 € 61,39
52-Weeksbereik
€ 46,06 € 61,39
Volume
500
50D / 200D Gem.
€ 48,27 / € 46,91
Vorige Slotkoers
€ 48,27

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,4
P/B 0,0 2,9
ROE % 12,7 3,7
Net Margin % 3,1 3,8
Rev Growth 5Y % 8,6 10,0
D/E 0,2 0,2

Belangrijkste Punten

Revenue grew 8,63% annually over 5 years — modest growth
Earnings grew 26,68% over the past year
ROE of 12,67% — decent returns on equity
Debt/Equity of 0,19 — conservative balance sheet
Negative free cash flow of -859,00M
P/E of 0,12 — trading at a low valuation

Groei

Revenue Growth (5Y)
8,63%
Revenue (1Y)4,81%
Earnings (1Y)26,68%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
12,67%
ROIC9,86%
Net Margin3,06%
Op. Margin3,99%

Veiligheid

Debt / Equity
0,19
Current Ratio0,75
Interest Coverage159,07

Waardering

P/E Ratio
0,12
P/B Ratio0,01
EV/EBITDA-0,08
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4,81% Revenue Growth (3Y) 10,54%
Earnings Growth (1Y) 26,68% Earnings Growth (3Y) 14,09%
Revenue Growth (5Y) 8,63% Earnings Growth (5Y) 3,35%
Profitability
Revenue (TTM) 1,01T Net Income (TTM) 30,98B
ROE 12,67% ROA 5,90%
Gross Margin 21,09% Operating Margin 3,99%
Net Margin 3,06% Free Cash Flow (TTM) -859,00M
ROIC 9,86% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,19 Current Ratio 0,75
Interest Coverage 159,07 Dividend Yield 0,01%
Valuation
P/E Ratio 0,12 P/B Ratio 0,01
P/S Ratio 0,00 PEG Ratio 0,63
EV/EBITDA -0,08 Dividend Yield 0,01%
Market Cap 3,83B Enterprise Value -3,26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,01T 964,99B 827,70B 755,41B 726,42B
Net Income 30,98B 24,45B 23,80B 23,16B 27,16B
EPS (Diluted) 390,86 308,61 600,95 584,74 685,77
Gross Profit 213,28B 188,31B 168,72B 151,45B 145,11B
Operating Income 40,40B 31,50B 30,13B 29,80B 33,15B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 524,76B 476,55B 420,97B 363,05B 341,32B
Total Liabilities 267,29B 245,11B 209,90B 172,55B 170,74B
Shareholders' Equity 257,46B 231,44B 211,07B 190,51B 170,58B
Total Debt 49,96B 34,06B 18,20B 9,41B 10,44B
Cash & Equivalents 57,04B 52,30B 45,93B 37,36B 55,11B
Current Assets 165,62B 154,33B 137,09B 115,47B 125,13B
Current Liabilities 220,68B 213,23B 192,05B 162,06B 159,54B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Value Defensive Investing (Benjamin Graham)
#374 of 708
27

Recente Activiteit

Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026